GT Biopharma ($GTBP): The TriKE® Platform, Clinical Progress, and the Case for NK Cell Immunotherapy

TriKE is a modular protein combining a tumor-binding domain, a camelid VHH that engages NK (natural killer) cells, and an IL-15 cytokine tail.

An early AML/MDS trial of first-generation TriKE produced NK cell expansion and bone-marrow blast reductions with only mild, self-limited side effects.

A second-generation camelid TriKE outperformed the first generation in a leukemia animal model and is now in Phase 1 dose escalation in patients.

B7H3-targeted GTB5550 is the first all-nanobody TriKE and is dosed subcutaneously in an outpatient solid-tumor basket trial that began dosing in May 2026.

Breen points to Phase 1 readouts in blood cancer and solid tumors by year-end 2026 and early 2027 as the milestones investors should track.